Sustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study.

被引：0
|
作者：
Hobart, J. [1 ,2 ]
Ziemssen, T. [3 ]
Feys, P. [4 ]
Linnebank, M. [5 ]
Goodman, A. [6 ]
Farrell, R. [7 ]
Englishby, V. [8 ]
McNeill, M. [8 ]
Chang, I. [9 ]
Mehta, L. [9 ]
Elkins, J. [9 ]
机构：
[1] Plymouth Univ, Peninsula Sch Med, Plymouth Hosp NHS Trust, Plymouth, Devon, England
[2] Plymouth Univ, Peninsula Sch Dent, Plymouth Hosp NHS Trust, Plymouth, Devon, England
[3] Univ Clin Dresden, Dresden, Germany
[4] Univ Hasselt, Diepenbeek, Belgium
[5] Univ Zurich Hosp, Zurich, Switzerland
[6] Univ Rochester, Sch Med & Dent, Rochester, NY USA
[7] Univ Coll London Hosp, Natl Hosp Neurol & Neurosurg, London, England
[8] Biogen, Maidenhead, Berks, England
[9] Biogen, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
254
引用
收藏
页码：833 / 834
页数：2
相关论文
共 50 条
  • [1] Prolonged-Release Fampridine Induces Sustained Clinically Meaningful Improvements in Walking Ability in People with Multiple Sclerosis: Results from the ENHANCE Trial
    Hobart, Jeremy
    Ziemssen, Tjalf
    Feys, Peter
    Linnebank, Michael
    Goodman, Andrew
    Farrell, Rachel
    Englishby, Veronica
    McNeill, Manjit
    Chang, Ih
    Mehta, Lahar
    Elkins, Jacob
    NEUROLOGY, 2017, 88
  • [2] Prolonged-release fampridine demonstrates rapid and sustained clinically meaningful improvements in walking ability over 24 weeks: MSWS-12 responders in the ENHANCE study
    Hobart, J.
    Ziemssen, T.
    Feys, P.
    Linnebank, M.
    Goodman, A.
    Farrell, R.
    Hupperts, R.
    Englishby, V.
    McNeill, M.
    Chang, I.
    Lima, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 434 - 435
  • [3] Multiple sclerosis patients with severe walking disability have clinically meaningful improvements in walking speed with prolonged-release fampridine
    Hartung, H. P.
    Goodman, A.
    Putzki, N.
    JOURNAL OF NEUROLOGY, 2011, 258 : 260 - 261
  • [4] Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine
    Sola-Valls, Nuria
    Blanco, Yolanda
    Sepulveda, Maria
    Llufriu, Sara
    Martinez-Lapiscina, Elena H.
    Zubizarreta, Irati
    Pulido-Valdeolivas, Irene
    Montejo, Carmen
    Villoslada, Pablo
    Saiz, Albert
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
  • [5] Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
    Jeremy Hobart
    Tjalf Ziemssen
    Peter Feys
    Michael Linnebank
    Andrew D. Goodman
    Rachel Farrell
    Raymond Hupperts
    Andrew R. Blight
    Veronica Englishby
    Manjit McNeill
    Ih Chang
    Gabriel Lima
    Jacob Elkins
    CNS Drugs, 2019, 33 : 61 - 79
  • [6] Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
    Hobart, Jeremy
    Ziemssen, Tjalf
    Feys, Peter
    Linnebank, Michael
    Goodman, Andrew D.
    Farrell, Rachel
    Hupperts, Raymond
    Blight, Andrew R.
    Englishby, Veronica
    McNeill, Manjit
    Chang, Ih
    Lima, Gabriel
    Elkins, Jacob
    CNS DRUGS, 2019, 33 (01) : 61 - 79
  • [7] Data from prolonged-release fampridine trials confirm that 20% improvement in walking speed is clinically meaningful
    Limmroth, V.
    Putzki, N.
    Goodman, A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S244 - S244
  • [8] Improved Walking Speed in Prolonged-Release Fampridine Timed Walk Responders May Translate to Improvements in Functional Walking Ability
    van Asch, Paul
    Goodman, Andrew
    NEUROLOGY, 2013, 80
  • [9] Prolonged-Release Fampridine Treatment and Walking Speed in Japanese Patients with MS: Design of the Multicentre, Double-Blind, Randomised, Placebo-Controlled MOTION-JAPAN Study.
    Saida, T.
    Yokoyama, K.
    Masaki, K.
    McNeill, M.
    Mehta, L. R.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (03) : 423 - 423
  • [10] Improved walking speed in prolonged-release fampridine timed-walk responders may translate to improvements in functional walking ability
    van Asch, P.
    JOURNAL OF NEUROLOGY, 2012, 259 : S211 - S212
12345